Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milind M Javle

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Expert Review of Gastroenterology & Hepatology|March 1, 2021
Next generation sequencing for biliary tract cancersTimothy P DiPeri, Milind M Javle, Funda Meric-Bernstam
Cancer|May 5, 2025
Poly(adenosine diphosphate ribose) polymerase inhibition in isocitrate dehydrogenase 1 and 2-mutant tumors: Bridging science with the clinicElise Nassif Haddad, Milind M Javle, Timothy A Yap
Oncology (Williston Park, N.Y.)|November 1, 2005
Neoadjuvant therapy for gastric cancerManpreet K Chadha, Boris W Kuvshinoff, Milind M Javle
International Journal of Cancer|December 4, 2004
Nuclear or cytoplasmic expression of survivin: what is the significance?Fengzhi Li, Jie Yang, Nithya Ramnath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Side effects of therapy: case 3. Gastric cancer after radiotherapy of pediatric Hodgkin's diseaseJ Alexander Palesty, Wei Wang, Milind M Javle, et al.
Angiology|May 17, 2006
Gemcitabine and acute myocardial infarction--a case reportFadi M Bdair, Susan P Graham, Patrick F Smith, et al.
Frontiers in Oncology|December 8, 2022
Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkersAshton A Connor, Sudha Kodali, Maen Abdelrahim, et al.
Hepato-Gastroenterology|November 10, 2004
Nuclear survivin expression predicts poor outcome in cholangiocarcinomaMilind M Javle, Dongfeng Tan, Jihnhee Yu, et al.
Journal of Gastrointestinal Oncology|December 2, 2014
Second-line systemic treatment for advanced cholangiocarcinomaJane E Rogers, Lindsey Law, Van D Nguyen, et al.
Annals of Surgical Oncology|August 21, 2007
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective studyRenuka V Iyer, John Gibbs, Boris Kuvshinoff, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Expert Review of Gastroenterology & Hepatology|March 1, 2021
Next generation sequencing for biliary tract cancersTimothy P DiPeri, Milind M Javle, Funda Meric-Bernstam
Cancer|May 5, 2025
Poly(adenosine diphosphate ribose) polymerase inhibition in isocitrate dehydrogenase 1 and 2-mutant tumors: Bridging science with the clinicElise Nassif Haddad, Milind M Javle, Timothy A Yap
Oncology (Williston Park, N.Y.)|November 1, 2005
Neoadjuvant therapy for gastric cancerManpreet K Chadha, Boris W Kuvshinoff, Milind M Javle
International Journal of Cancer|December 4, 2004
Nuclear or cytoplasmic expression of survivin: what is the significance?Fengzhi Li, Jie Yang, Nithya Ramnath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Side effects of therapy: case 3. Gastric cancer after radiotherapy of pediatric Hodgkin's diseaseJ Alexander Palesty, Wei Wang, Milind M Javle, et al.
Angiology|May 17, 2006
Gemcitabine and acute myocardial infarction--a case reportFadi M Bdair, Susan P Graham, Patrick F Smith, et al.
Frontiers in Oncology|December 8, 2022
Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkersAshton A Connor, Sudha Kodali, Maen Abdelrahim, et al.
Hepato-Gastroenterology|November 10, 2004
Nuclear survivin expression predicts poor outcome in cholangiocarcinomaMilind M Javle, Dongfeng Tan, Jihnhee Yu, et al.
Journal of Gastrointestinal Oncology|December 2, 2014
Second-line systemic treatment for advanced cholangiocarcinomaJane E Rogers, Lindsey Law, Van D Nguyen, et al.
Annals of Surgical Oncology|August 21, 2007
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective studyRenuka V Iyer, John Gibbs, Boris Kuvshinoff, et al.
Pageof 7